Merck: mixed results in esophageal adenocarcinoma
(CercleFinance.com) - Merck announces that the phase 3 trial evaluating the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) with chemotherapy for the first-line treatment of patients with HER2-negative advanced gastroesophageal adenocarcinoma showed a significant improvement in progression-free survival (PFS) and objective response rate (ORR).
However, the trial failed to meet its other primary objective, that of overall survival (OS).
Treatment safety was consistent with previous studies.
Full results will be presented at a future medical congress.
Copyright (c) 2025 CercleFinance.com. All rights reserved.